Could a diabetes pill shield kids' kidneys from protein damage?
NCT ID NCT07204743
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 27 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can reduce protein in the urine and protect kidney function in children aged 4–18 with persistent proteinuria despite standard therapy. Ten participants will have their protein levels and kidney function measured before and after treatment. The goal is to see if this drug can help control kidney disease in children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Al Ahli hospital
Hebron, Palestine, P700, Palestinian Territories
Conditions
Explore the condition pages connected to this study.